Fresenius Kabi
Stimufend
Manufacturer:
Fresenius Kabi
Name:
Stimufend
HCPCS Code Descriptor:
Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg
Category:
Q Code
HCPCS:
Q5127
NDC(s):
65219-0371-10
Primary Type:
Oncology Biosimilar Colony Stimulating Factor
Generic Status:
Single-Source
Route of Administration:
Subcutaneous
About:
Stimufend is an Oncology Biosimilar Colony Stimulating Factor drug manufactured by Fresenius Kabi and administered via the Subcutaneous route of administration. The Q Code: Q5127 is aligned to the drug Stimufend.
Stimufend is used to prevent the lack of the white blood cells known as neutrophils. Stimufend is an artificial protein that aids in the production of neutrophils. This medication is manufactured by Fresenius Kabi USA and is biosimilar to the product Neulasta (J2506). The HCPCS code for Stimufend is Q5127, this HCPCS code was aligned to Stimufend in April 2023.